The recent FDA approval of Tamiflu oseltamivir to prevent influenza infection comes in a flu season where there is a shortage of available vaccine. But the neuraminidase inhibitor developed by Gilead Sciences Inc. and partner F. Hoffmann-La Roche Ltd. will not be replacing flu shots anytime soon, as both physicians and Roche agree that flu vaccinations remain the first line of defense against the virus, and that Tamiflu will be essentially reserved for certain subsets of